EMDocs

AUGUST 31, 2023

Accessed May 7, 2022. Accessed May 7, 2022. Accessed May 7, 2022. Accessed May 7, 2022. Bush SP, Ruha AM, Seifert SA, et al. StatPearls Publishing; 2022. Accessed May 17, 2022. link] Kanaan NC, Ray J, Stewart M, et al. link] Kanaan NC, Ray J, Stewart M, et al. Ann Emerg Med.

Allergic Reaction 96

Allergic Reaction Plasma ALS EMS 96

EMDocs

FEBRUARY 7, 2024

American Gastroenterological Association issued a practice guideline in November 2022 recommending that semaglutide 2.4 Retrospective study published in 2022 of 81,752 adverse events associated with GLP-1 agonist therapy found an increased risk of pancreatitis, particularly with liraglutide (ROR 32.67; 95% CI 29.44-36.25).

Allergic Reaction 97

Allergic Reaction ALS CAD OR 97

REBEL EM

AUGUST 3, 2023

Paper: Copaescu AM et al. What They Did: Parallel, 2-arm, noninferiority, open-label, multicenter, international randomized clinical trial Occurred in 6 specialized centers (3 in North America – US & Canada and 3 Outside of North America – Australia) Trial took place from June 2021 to December 2022 Used PEN-FAST to risk stratify patients.

Allergic Reaction 52

Allergic Reaction OR ALS Emergency Department 52

EMDocs

NOVEMBER 13, 2023

2 Outcomes of patients presenting with ischemic stroke who received MRI as initial imaging modality have demonstrated similar outcomes to those with initial CTA, with Kim et al. In a study of 17,903 CTAs ordered in the ED, Tu et al. 8 The data in Mayer et al. 9 A later assessment of the VAN score in Beume et al.

E-9-1-1 105

E-9-1-1 ALS Emergency Department ED 105

EMDocs

JANUARY 25, 2025

link] Laxminarayana SLK, Jayaram S, Swaminathan SM et al. Philadelphia, PA: Elsevier; 2022:1-11. doi:10.1016/B978-0-323-69578-7.00001-6 Mart, Gulay et al. 101,33 (2022): e30116. Updated 2022 Nov 14]. 10^9/L) Moderate (0.50.9 10^9/L) Severe (< 0.5 10^9/L) Generalized leukopenia (i.e. Medications: 25.6%

E-9-1-1 94

E-9-1-1 EMS Allergic Reaction ED 94

This Podcast Will Kill You

JANUARY 14, 2025

Cataldi, Mauro, et al. Gutermuth, Jan, et al. “111 years of allergen-immunotherapy: a long and successful history of the only available disease-modifier in allergic diseases.” ” Allergologie select 6 (2022): 248. Development of neffy, an Epinephrine Nasal Spray, for Severe Allergic Reactions.

Allergic Reaction 52

Allergic Reaction E-9-1-1 Epinephrine ALS 52

This Podcast Will Kill You

JANUARY 7, 2025

Sometimes it seems like the world is out to get us: bees in our garden, pollen in the air, nuts in our brownies, any number of other things that could trigger an allergic reaction ranging from itchy eyes and a runny nose all the way to anaphylaxis. Hurley, Sadhbh, et al. Lv, Jia-jie, et al. Marichal, Thomas, et al.

E-9-1-1 52

E-9-1-1 Allergic Reaction PIER ALS 52